Oak Therapeutics Inc.
Westlake Village, CA Doing business as Nobilis Pharma
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 31416 Agoura Rd #105e, Westlake Village, CA 91361, USA
- Website
- oaktherapeutics.com
- Founded
- 2014
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Oral dissolving strips for the delivery of isoniazid in children and adults | National Institute of Allergy and Infectious Diseases (NIH) | $220,582 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Adepthera LLC | Palo Alto, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Zylo Therapeutics, Inc. | Greenville, SC | 325412 Pharmaceutical Preparation Manufacturing |
| Intact Therapeutics | Palo Alto, CA | — |
| Consegna Pharma Inc. | Pittsburgh, PA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Therapeutic Systems Research Laboratories | Ann Arbor, MI | — |
About the company
Oak Therapeutics Inc. is a pharmaceutical company that specializes in reformulating active pharmaceutical ingredients into novel delivery formats such as oral dissolvable strips. They focus on increasing treatment adherence for populations including pediatrics and geriatrics.
Oak Therapeutics has been awarded two federal grants from the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop new drug formulations and delivery methods. This includes a $273,458 project grant to develop an oral dissolvable strip for treating latent tuberculosis, with the goal of improving patient adherence and outcomes. Additionally, Oak Therapeutics received a $433,692 project grant to create the first orally dissolvable pediatric product encapsulating a combination of three antiretroviral medications used to treat HIV. Through the grants, Oak Therapeutics provides research and development services focused on reformulating drug compounds into innovative delivery mechanisms that can simplify administration and increase adherence for difficult-to-treat patients. As a sub-awardee, Oak Therapeutics also contributes technical expertise in oral dissolvable strip development to a project led by the University of Kansas Medical Center Research Institute.
Quick answers
Is Oak Therapeutics Inc. registered in SAM.gov?
Yes. Oak Therapeutics Inc.'s SAM.gov registration is active through April 25, 2027.
What is Oak Therapeutics Inc.'s CAGE code?
Oak Therapeutics Inc.'s CAGE code is 7C565, and its Unique Entity ID (UEI) is SJ7GGFACQTJ5.
What is Oak Therapeutics Inc.'s most recent federal award?
Oak Therapeutics Inc.'s most recent federal grant award is Oral dissolvable strips (ODS) as new pediatric and adult delivery mode of therapy for latent tuberculosis (R44AI179391), from National Institute of Allergy and Infectious Diseases (NIH), on September 1, 2023.
On GovTribe
See Oak Therapeutics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors